Dr. Hope Rugo explains what is the Oncotype DX Breast Cancer Assay and how is it performed, detailing the specificities of the test, especially how the Recurrence Score result of the Oncotype DX Breast Cancer Assay is reported.

She highlights the way, she and her multidisciplinary team, choose to use a genomic test such as the Oncotype DX Breast Cancer Assay to make adjuvant chemotherapy decisions in luminal breast cancers.

She comments on the way to use the Oncotype DX Breast Cancer Assay: does it complement or compete with traditional markers or other markers such ER, PR or HER2? She mentions that the Recurrence Score result is very complementary and clarifies for which patients (ER-positive, HER2-, node positive or node negative) the Oncotype DX Breast Cancer Assay is indicated.

Her conclusion is that the information from the Oncotype DX Breast Cancer Assay clearly supports the patient discussions.

This programme has been supported by sponsorship from Genomic Health.